# ADME Study of [14C]- Rongliflozin in Healthy Male Subjects

> **NCT05109078** · PHASE1 · COMPLETED · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 6 (actual)

## Conditions studied

- Healthy Adult Male Volunteers

## Interventions

- **DRUG:** [14C]- Rongliflozin

## Key facts

- **NCT ID:** NCT05109078
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-09
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05109078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05109078, "ADME Study of [14C]- Rongliflozin in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05109078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*